• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.41
+0 (0.00%)

This chart shows the closing price for CYDY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CytoDyn Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYDY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYDY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for CytoDyn in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.41.

This chart shows the closing price for CYDY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in CytoDyn. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/17/2020HC WainwrightReiterated RatingHold
7/22/2020HC WainwrightReiterated RatingHold
7/14/2020HC WainwrightReiterated RatingHold
7/6/2020HC WainwrightDowngradeBuy ➝ Neutral
6/12/2020HC WainwrightReiterated RatingBuy$4.00
4/28/2020HC WainwrightReiterated RatingBuy$3.00 ➝ $4.00
4/13/2020HC WainwrightReiterated RatingBuy$3.00
4/3/2020HC WainwrightReiterated RatingBuy$1.50 ➝ $3.00
3/6/2020HC WainwrightReiterated RatingBuy$1.50
12/19/2019HC WainwrightReiterated RatingBuy$1.00 ➝ $1.50
9/16/2019HC WainwrightReiterated RatingBuy$1.50 ➝ $1.00
6/18/2019HC WainwrightReiterated RatingBuy
5/8/2019HC WainwrightSet TargetBuy$2.00
4/12/2019HC WainwrightSet TargetBuy$2.00
3/18/2019HC WainwrightReiterated RatingBuy$1.50
3/5/2019HC WainwrightSet TargetBuy$2.00
2/20/2019HC WainwrightReiterated RatingBuy$2.00
11/27/2018HC WainwrightInitiated CoverageBuy$2.00
11/13/2018HC WainwrightSet TargetBuy$2.00
11/6/2018HC WainwrightSet TargetBuy$2.00
10/10/2018HC WainwrightSet TargetBuy$2.00
9/14/2018HC WainwrightSet TargetBuy$2.00
9/6/2018HC WainwrightSet TargetBuy$2.00
8/16/2018HC WainwrightSet TargetBuy$2.00
7/31/2018HC WainwrightSet TargetBuy$2.00
7/13/2018HC WainwrightSet TargetBuy$2.00
5/25/2018HC WainwrightSet TargetBuy$2.00
3/9/2018HC WainwrightSet TargetBuy$2.00
2/13/2018HC WainwrightSet TargetBuy$2.00
12/8/2017HC WainwrightReiterated RatingBuy
11/29/2017HC WainwrightReiterated RatingBuy
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/7/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/4/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
CytoDyn logo
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Read More

Today's Range

Now: $0.41
Low: $0.39
High: $0.42

50 Day Range

MA: $0.67
Low: $0.42
High: $1.23

52 Week Range

Now: $0.41
Low: $0.23
High: $1.87

Volume

1,050,055 shs

Average Volume

2,558,527 shs

Market Capitalization

$334.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07

Frequently Asked Questions

What sell-side analysts currently cover shares of CytoDyn?

The following sell-side analysts have issued research reports on CytoDyn in the last year:
View the latest analyst ratings for CYDY.

What is the current price target for CytoDyn?

0 Wall Street analysts have set twelve-month price targets for CytoDyn in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CytoDyn in the next year.
View the latest price targets for CYDY.

What is the current consensus analyst rating for CytoDyn?

CytoDyn currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CYDY.

What other companies compete with CytoDyn?

How do I contact CytoDyn's investor relations team?

CytoDyn's physical mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company's listed phone number is (360) 980-8524 and its investor relations email address is [email protected] The official website for CytoDyn is www.cytodyn.com. Learn More about contacing CytoDyn investor relations.